Lamotrigine can be beneficial in patients with Dravet syndrome.

Détails

ID Serval
serval:BIB_4571A587B978
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Titre
Lamotrigine can be beneficial in patients with Dravet syndrome.
Périodique
Developmental Medicine and Child Neurology
Auteur(s)
Dalic L., Mullen S.A., Roulet Perez E., Scheffer I.
ISSN
1469-8749 (Electronic)
ISSN-L
0012-1622
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
57
Numéro
2
Pages
200-202
Langue
anglais
Notes
Publication types: Journal ArticlePublication Status: ppublish
Résumé
Dravet syndrome, a severe infantile epilepsy syndrome, is typically resistant to anti-epileptic drugs (AED). Lamotrigine (LTG), an AED that is effective for both focal and generalized seizures, has been reported to aggravate seizures in Dravet syndrome. Therefore, LTG is usually avoided in Dravet syndrome. We describe two adults and a child with Dravet syndrome in whom LTG resulted in decreased seizure duration and frequency. This benefit was highlighted in each patient when LTG was withdrawn after 6 to 15 years, and resulted in an increased frequency of convulsive seizures together with longer seizure duration. A 25-year-old male required hospital admission for frequent seizures for the first time in 7 years, 6 weeks after ceasing LTG. Reintroduction of LTG improved seizure control, suggesting that in some patients with Dravet syndrome, LTG may be beneficial.
Pubmed
Web of science
Open Access
Oui
Création de la notice
07/02/2015 14:56
Dernière modification de la notice
20/08/2019 14:50
Données d'usage